The stock of Replimune Group Inc (REPL) has gone down by -3.07% for the week, with a -7.99% drop in the past month and a 8.97% rise in the past quarter. The volatility ratio for the week is 4.82%, and the volatility levels for the past 30 days are 5.24% for REPL.. The simple moving average for the past 20 days is -6.28% for REPL’s stock, with a 21.29% simple moving average for the past 200 days.
Is It Worth Investing in Replimune Group Inc (NASDAQ: REPL) Right Now?
The stock has a 36-month beta value of 1.21. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for REPL is 54.53M, and at present, short sellers hold a 12.93% of that float. On November 22, 2024, the average trading volume of REPL was 652.13K shares.
REPL) stock’s latest price update
The stock price of Replimune Group Inc (NASDAQ: REPL) has dropped by -1.60 compared to previous close of 11.23. Despite this, the company has seen a fall of -3.07% in its stock price over the last five trading days. globenewswire.com reported 2024-11-21 that WOBURN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it has submitted a biologics license application (BLA) to the FDA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The submission was made under the Accelerated Approval pathway. The Company also announced that the FDA has granted Breakthrough Therapy designation to RP1 in combination with nivolumab in the same setting.
Analysts’ Opinion of REPL
Many brokerage firms have already submitted their reports for REPL stocks, with ROTH MKM repeating the rating for REPL by listing it as a “Buy.” The predicted price for REPL in the upcoming period, according to ROTH MKM is $17 based on the research report published on August 28, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see REPL reach a price target of $44. The rating they have provided for REPL stocks is “Overweight” according to the report published on April 17th, 2023.
Piper Sandler gave a rating of “Overweight” to REPL, setting the target price at $52 in the report published on November 19th of the previous year.
REPL Trading at -4.01% from the 50-Day Moving Average
After a stumble in the market that brought REPL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.80% of loss for the given period.
Volatility was left at 5.24%, however, over the last 30 days, the volatility rate increased by 4.82%, as shares sank -7.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.45% upper at present.
During the last 5 trading sessions, REPL fell by -3.07%, which changed the moving average for the period of 200-days by +48.92% in comparison to the 20-day moving average, which settled at $11.79. In addition, Replimune Group Inc saw 31.08% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REPL starting from Xynos Konstantinos, who sale 7,246 shares at the price of $10.78 back on Nov 18 ’24. After this action, Xynos Konstantinos now owns 109,885 shares of Replimune Group Inc, valued at $78,112 using the latest closing price.
Sarchi Christopher, the Chief Commercial Officer of Replimune Group Inc, sale 5,207 shares at $10.78 during a trade that took place back on Nov 18 ’24, which means that Sarchi Christopher is holding 87,045 shares at $56,131 based on the most recent closing price.
Stock Fundamentals for REPL
Current profitability levels for the company are sitting at:
- -57.29 for the present operating margin
- 0.48 for the gross margin
The net margin for Replimune Group Inc stands at -52.7. The total capital return value is set at -0.51. Equity return is now at value -50.32, with -40.17 for asset returns.
Based on Replimune Group Inc (REPL), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -3.97. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -31.16.
Currently, EBITDA for the company is -230.2 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 177.79. The receivables turnover for the company is 4.86for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.11.
Conclusion
To sum up, Replimune Group Inc (REPL) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
